Breakthrough Medicines for Fibrosis-Driven Diseases

Breakthrough Medicines for Fibrosis-Driven Diseases

Clinical Trial

Clinical Trial

Who We Are

Tvardi Therapeutics is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.

Tvardi Current News

Tvardi Named 2021 Winner of Fierce 15 Biotech

Fierce Biotech has named Tvardi Therapeutics as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising biotechnology companies in the industry.

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.